Alkem Laboratories Navigates Q3 FY26 with Strategic Expansion and Robust International Growth

Alkem Laboratories Ltd. has announced its standalone and consolidated financial results for the third quarter ended December 31, 2025, showcasing a period of strategic expansion and resilient performance. The company reported a total revenue from operations of INR3736.8 crore, marking a healthy 10.7% year-on-year growth. Despite this strong top-line performance, profit after tax (PAT) saw a more modest increase of 1.6% year-on-year, reaching INR636 crore. This quarter's narrative is largely defined by a significant foray into the medical devices segment, alongside consistent execution in its core pharmaceutical markets.

The company's financial health is underpinned by a strong operational performance. Earnings before Interest, Tax, Depreciation, and Amortisation (EBITDA) stood at INR828 crore, growing 9.0% year-on-year, with an EBITDA margin of 22.2%. Research and Development (R&D) expenses for the quarter were INR139 crore, representing 3.7% of total revenue from operations. This investment underscores Alkem's commitment to innovation and pipeline development. Profit before tax (PBT) after exceptional items was INR781.2 crore, reflecting a 6.9% year-on-year growth.

Segmental Performance: Domestic Resilience, International Surge

Alkem's performance across its key segments demonstrated a mixed but generally positive trend. The domestic business recorded sales of INR2495.9 crore, growing 5.5% year-on-year. This segment contributed 66.79% to the total revenue from operations. Management noted that while Q3 FY25 had a high base due to distribution setup adjustments, the underlying prescription business is growing strongly. The chronic business, in particular, showed a very strong growth trajectory.

In contrast, the international business was a significant growth driver, surging 26.6% year-on-year to reach INR1215.7 crore, accounting for 32.53% of total revenue. Within this, US sales grew by 18.8% to INR753.3 crore, primarily driven by new launches and volume increases. Non-US sales demonstrated even more impressive growth, expanding by 41.6% to INR462.4 crore, fueled by strong performance across all markets. The company also reported filing 2 ANDAs and receiving 7 ANDA approvals during Q3 FY26, bringing its total filings to 188 ANDAs, 2 NDAs, and 1 BLA, with 167 ANDAs and 2 NDAs approved as of December 31, 2025.

Alkem's market outperformance is evident in its IQVIA (SSA) data, where it outpaced the Indian Pharmaceutical Market (IPM) in six key therapy areas: anti-infectives (1.4x growth), vitamins and minerals (2.0x), pain (1.4x), anti-diabetic (1.2x, over 2x when adjusting for GLP-1), respiratory (1.2x), and derma (1.8x). The company also outperformed in the acute segment by 80 bps and marginally in the chronic category by 18 bps.

Strategic Leap into MedTech and Future Outlook

The most significant development this quarter is Alkem's strategic entry into the medical devices segment through the acquisition of a majority stake in Occlutech Holding AG. This move is a cornerstone of Alkem's ambition to establish a global footprint in medical devices, focusing on minimally invasive cardiac implants, cardiovascular, and orthopaedics. Occlutech, already the third-largest player globally in its niche, brings a strong R&D setup, manufacturing capabilities, and a significant presence in high-barrier markets like Western Europe and the US.

Management anticipates Occlutech's revenue to reach approximately INR100 crore within 3-5 years, with EBITDA margins potentially hitting 20-25%. An additional investment of INR20-30 crore is planned over the next 3-4 years to accelerate R&D projects, including the Left Atrial Appendage (LA) product, which is expected to launch in Europe. The company also aims to expand Occlutech's footprint in emerging markets, leveraging its existing product portfolio. The PFO (Patent Foramen Ovale) occluder is expected to launch in the US by June 2027, with an anticipated average selling price (ASP) of around $9,500.

Financial Summary Table (Q3 FY26)

Addressing Challenges and Maintaining Momentum

Despite the positive momentum, Alkem acknowledged certain challenges. An exceptional item of INR52.8 crore was recorded for Q3 FY26, related to the newly notified Labour Codes. The trade generic business experienced flat growth for the quarter and lower single-digit growth year-to-date, with EBITDA margins slightly lower than the corporate average. The company is also assessing the potential cost impact of INR8-10 crore from the Minimum Import Price (MIP) on PenG derivatives, though it expects some offset through market pricing adjustments.

Management, however, remains bullish on the company's overall growth trajectory. They expect the domestic business to continue growing 100-150 basis points faster than the IPM. The company is also gearing up for the launch of GLP-1 semaglutide in March 2026, which is anticipated to be a key growth driver. The refinancing of Occlutech's high-interest debt with a corporate guarantee is expected to reduce interest costs significantly, improving the acquired entity's profitability.

Alkem Laboratories' Q3 FY26 results reflect a company in transition, strategically expanding into new, high-growth areas like medical devices while solidifying its position in core pharmaceutical markets. The focus on R&D, market outperformance, and disciplined capital allocation positions Alkem for sustained growth and enhanced value creation in the evolving healthcare landscape.